SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[_] Definitive Additional Materials
[X] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
[Letterhead of ICN Pharmaceuticals, Inc.]
Letter to Richard H. Koppes from ICN Pharmaceuticals
Costa Mesa, CA, April 23, 2002 -- ICN Pharmaceuticals, Inc. (NYSE:ICN)
released the text of a letter, set forth below, sent today to Richard H.
Koppes, one of ICN's three nominees for election to its board of directors.
Dear Mr. Koppes:
We received your letter of April 22, 2002 and are glad you are willing
to serve as a director of ICN Pharmaceuticals, Inc.
While we differ with you on the issue of which candidates will best
serve ICN at this time, we accept that you will advocate the candidacy of
Randy Thurman, Robert O'Leary and yourself and advocate against the
election of Senator Birch Bayh and Abraham Cohen as ICN directors.
We take comfort from the fact that you have not disavowed your prior
promises to the Nominating Committee, that you will keep an open mind, that
you have no agreements or understandings with Iridian or Franklin, and that
if elected as a director (which we hope you will be) you will act in the
best interests of all stockholders. In order to avoid any confusion as to
your activities in connection with the upcoming annual meeting, we intend
to publish your two letters in full in ICN's proxy statement.
Very truly yours,
Alan F. Charles
Executive Vice President, Corporate Relations
ICN Pharmaceuticals, Inc.
ICN has filed a preliminary proxy statement relating to ICN's 2002 annual
meting of stockholders with the Securities and Exchange Commission on April
19, 2002 and will file with the SEC and forward to ICN stockholders a
definitive proxy statement. ICN stockholders are strongly advised to read
the definitive proxy statement when it becomes available, as it will
contain important information. Stockholders may obtain the preliminary
proxy statement and will be able to obtain the definitive proxy statement,
when available, and any amendments to the proxy statement and other
documents filed by ICN with the SEC for free at the Internet website
maintained by the SEC at www.sec.gov. In addition, ICN will mail the
definitive proxy statement to each stockholder of record on April 9, 2002.
ICN will also make additional copies of the definitive proxy statement and
any amendments to the definitive proxy statement available for free to
ICN's stockholders. Please direct your request for the definitive proxy
statement to Investor Relations, ICN Pharmaceuticals, Inc., 3300 Hyland
Avenue, Costa Mesa, California 92626, telephone (714) 545-0100, extension
3013.
ICN, its executive officers and directors and director nominees may be
deemed to be participants in the solicitation of proxies for ICN's 2002
annual meeting of stockholders. Information regarding these participants is
contained in the preliminary proxy statement filed with the SEC on April
19, 2002.
THE 'SAFE HARBOR' STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995. This press release contains forward-looking statements that
involve risks and uncertainties, including but not limited to, projections
of future sales, operating income returns on invested assets, regulatory
approval processes, and other risks detailed from time to time in the
Company's Securities and Exchange Commission filings.
####